Aier Eye Hospital Group Co., Ltd. Logo

Aier Eye Hospital Group Co., Ltd.

300015.SZ

(4.0)
Stock Price

14,89 CNY

16.01% ROA

19.28% ROE

47.73x PER

Market Cap.

176.418.687.546,00 CNY

13.51% DER

0.79% Yield

17.9% NPM

Aier Eye Hospital Group Co., Ltd. Stock Analysis

Aier Eye Hospital Group Co., Ltd. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Aier Eye Hospital Group Co., Ltd. Fundamental Stock Analysis
# Analysis Rating
1 ROE

The stock's ROE exceeds expectations (18.75%), revealing strong profitability and efficient use of shareholders' equity, making it an attractive investment opportunity.

2 ROA

The stock's ability to make a lot of money from its assets shows that it is very profitable, making it a good choice for people who want to invest and make a lot of money.

3 DER

The stock has a minimal amount of debt (25%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

4 Revenue Growth

With a track record of consistent revenue growth in the past five years, this company presents a compelling opportunity.

5 Net Profit Growth

Throughout the past five years, this company has consistently experienced net profit growth, indicating a strong financial performance and making it an attractive investment prospect.

6 Assets Growth

With continuous growth in revenue over the last five years, this company has proven to be a lucrative investment option, showcasing its strong financial performance.

7 Dividend

The company's consistent dividend payouts over the past five years exemplify its strong commitment to providing shareholders with reliable returns, making it an attractive investment option.

8 Dividend Growth

With a history of consistent dividend increases over the last three years, the company has proven to be a reliable choice for investors seeking reliable income.

9 Buffet Intrinsic Value

The company's stock seems undervalued (93) by Warren Buffett's formula, indicating a promising investment opportunity as its intrinsic value exceeds the market price.

10 PBV

The stock's elevated P/BV ratio (6.56x) raises concerns about its overvaluation, making it an imprudent choice for investors seeking value.

11 Graham Number

The Graham number calculation reveals that this company's stock price is potentially inflated, implying that it may not be a desirable investment option.

Aier Eye Hospital Group Co., Ltd. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Aier Eye Hospital Group Co., Ltd. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Sell
3 RSI Hold
4 Stoch RSI Buy

Aier Eye Hospital Group Co., Ltd. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Aier Eye Hospital Group Co., Ltd. Revenue
Year Revenue Growth
2006 191.188.834
2007 314.903.815 39.29%
2008 439.120.734 28.29%
2009 606.450.103 27.59%
2010 864.877.450 29.88%
2011 1.310.624.472 34.01%
2012 1.640.130.450 20.09%
2013 1.984.967.287 17.37%
2014 2.402.047.616 17.36%
2015 3.165.580.471 24.12%
2016 4.000.401.671 20.87%
2017 5.962.845.559 32.91%
2018 8.008.573.954 25.54%
2019 9.990.103.976 19.83%
2020 11.912.409.984 16.14%
2021 15.000.809.438 20.59%
2022 16.109.946.687 6.88%
2023 23.181.633.685 30.51%
2023 20.367.156.738 -13.82%
2024 21.341.422.248 4.57%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Aier Eye Hospital Group Co., Ltd. Research and Development Expenses
Year Research and Development Expenses Growth
2006 0
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 3.092.070 100%
2013 4.102.381 24.63%
2014 9.579.954 57.18%
2015 18.099.594 47.07%
2016 21.914.534 17.41%
2017 30.593.918 28.37%
2018 97.494.715 68.62%
2019 152.312.083 35.99%
2020 164.248.131 7.27%
2021 222.549.895 26.2%
2022 271.719.403 18.1%
2023 393.102.767 30.88%
2023 333.488.746 -17.88%
2024 271.720.936 -22.73%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Aier Eye Hospital Group Co., Ltd. General and Administrative Expenses
Year General and Administrative Expenses Growth
2006 53.996.805
2007 84.081.690 35.78%
2008 102.155.101 17.69%
2009 136.478.164 25.15%
2010 53.364.135 -155.75%
2011 84.408.910 36.78%
2012 95.324.400 11.45%
2013 117.113.985 18.61%
2014 122.439.097 4.35%
2015 143.145.736 14.47%
2016 198.208.684 27.78%
2017 275.654.787 28.1%
2018 325.958.179 15.43%
2019 392.590.402 16.97%
2020 365.934.802 -7.28%
2021 442.095.075 17.23%
2022 499.221.926 11.44%
2023 7.049.790.423 92.92%
2023 636.944.442 -1006.81%
2024 -1.438.173.959 144.29%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Aier Eye Hospital Group Co., Ltd. EBITDA
Year EBITDA Growth
2006 47.168.622
2007 94.835.038 50.26%
2008 118.334.315 19.86%
2009 170.953.599 30.78%
2010 241.280.312 29.15%
2011 326.279.527 26.05%
2012 353.141.752 7.61%
2013 433.616.405 18.56%
2014 536.929.061 19.24%
2015 739.519.952 27.39%
2016 848.150.823 12.81%
2017 1.294.737.820 34.49%
2018 1.882.441.351 31.22%
2019 2.671.673.275 29.54%
2020 3.680.279.104 27.41%
2021 5.065.766.982 27.35%
2022 5.204.877.493 2.67%
2023 7.859.232.584 33.77%
2023 6.666.571.695 -17.89%
2024 6.922.472.960 3.7%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Aier Eye Hospital Group Co., Ltd. Gross Profit
Year Gross Profit Growth
2006 98.723.011
2007 177.106.671 44.26%
2008 243.398.522 27.24%
2009 346.247.157 29.7%
2010 487.533.969 28.98%
2011 725.197.253 32.77%
2012 737.630.696 1.69%
2013 910.991.540 19.03%
2014 1.078.841.715 15.56%
2015 1.474.921.154 26.85%
2016 1.844.593.147 20.04%
2017 2.759.772.481 33.16%
2018 3.763.765.512 26.68%
2019 4.925.551.303 23.59%
2020 6.078.583.675 18.97%
2021 7.788.922.151 21.96%
2022 8.129.557.884 4.19%
2023 13.052.630.368 37.72%
2023 10.345.181.746 -26.17%
2024 10.592.297.964 2.33%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Aier Eye Hospital Group Co., Ltd. Net Profit
Year Net Profit Growth
2006 14.591.521
2007 38.979.516 62.57%
2008 61.366.555 36.48%
2009 92.489.402 33.65%
2010 120.309.791 23.12%
2011 171.927.760 30.02%
2012 182.546.813 5.82%
2013 223.495.554 18.32%
2014 309.186.277 27.71%
2015 428.043.981 27.77%
2016 557.467.244 23.22%
2017 742.514.537 24.92%
2018 1.008.937.348 26.41%
2019 1.378.920.970 26.83%
2020 1.723.805.335 20.01%
2021 2.323.343.957 25.8%
2022 2.524.230.840 7.96%
2023 5.875.524.836 57.04%
2023 3.358.871.535 -74.93%
2024 4.601.618.224 27.01%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Aier Eye Hospital Group Co., Ltd. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2006 0
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Aier Eye Hospital Group Co., Ltd. Free Cashflow
Year Free Cashflow Growth
2006 -76.334.882
2007 -3.750.352 -1935.41%
2008 30.378.590 112.35%
2009 21.515.081 -41.2%
2010 -6.336.911 439.52%
2011 -3.646.412 -73.78%
2012 75.652.833 104.82%
2013 217.936.700 65.29%
2014 277.027.257 21.33%
2015 261.366.004 -5.99%
2016 360.515.893 27.5%
2017 724.853.281 50.26%
2018 589.183.524 -23.03%
2019 1.332.806.924 55.79%
2020 2.449.902.225 45.6%
2021 2.590.015.683 5.41%
2022 3.102.438.543 16.52%
2023 1.722.245.405 -80.14%
2023 4.412.181.485 60.97%
2024 1.149.565.522 -283.81%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Aier Eye Hospital Group Co., Ltd. Operating Cashflow
Year Operating Cashflow Growth
2006 36.904.489
2007 92.187.299 59.97%
2008 121.174.149 23.92%
2009 169.137.874 28.36%
2010 239.966.170 29.52%
2011 257.108.449 6.67%
2012 301.818.986 14.81%
2013 412.651.458 26.86%
2014 453.683.706 9.04%
2015 522.168.231 13.12%
2016 675.098.166 22.65%
2017 1.330.404.512 49.26%
2018 1.399.870.398 4.96%
2019 2.078.432.734 32.65%
2020 3.343.611.325 37.84%
2021 4.084.103.958 18.13%
2022 4.490.674.811 9.05%
2023 2.205.196.618 -103.64%
2023 5.871.890.091 62.44%
2024 1.683.962.769 -248.69%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Aier Eye Hospital Group Co., Ltd. Capital Expenditure
Year Capital Expenditure Growth
2006 113.239.371
2007 95.937.651 -18.03%
2008 90.795.558 -5.66%
2009 147.622.792 38.49%
2010 246.303.081 40.06%
2011 260.754.861 5.54%
2012 226.166.153 -15.29%
2013 194.714.758 -16.15%
2014 176.656.448 -10.22%
2015 260.802.227 32.26%
2016 314.582.273 17.1%
2017 605.551.230 48.05%
2018 810.686.874 25.3%
2019 745.625.810 -8.73%
2020 893.709.099 16.57%
2021 1.494.088.275 40.18%
2022 1.388.236.267 -7.62%
2023 482.951.213 -187.45%
2023 1.459.708.606 66.91%
2024 534.397.247 -173.15%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Aier Eye Hospital Group Co., Ltd. Equity
Year Equity Growth
2006 149.984.155
2007 230.831.329 35.02%
2008 261.990.027 11.89%
2009 1.233.880.249 78.77%
2010 1.308.593.205 5.71%
2011 1.413.283.704 7.41%
2012 1.568.889.013 9.92%
2013 1.738.790.940 9.77%
2014 2.097.376.848 17.1%
2015 2.499.205.040 16.08%
2016 2.937.036.974 14.91%
2017 5.472.047.112 46.33%
2018 5.970.549.520 8.35%
2019 7.022.731.424 14.98%
2020 10.652.175.673 34.07%
2021 12.224.067.096 12.86%
2022 17.615.469.368 30.61%
2023 20.024.761.539 12.03%
2023 19.815.655.244 -1.06%
2024 20.580.916.113 3.72%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Aier Eye Hospital Group Co., Ltd. Assets
Year Assets Growth
2006 333.048.099
2007 358.215.696 7.03%
2008 396.507.446 9.66%
2009 1.411.961.297 71.92%
2010 1.612.827.799 12.45%
2011 1.721.842.000 6.33%
2012 1.929.818.183 10.78%
2013 2.118.840.830 8.92%
2014 2.550.430.405 16.92%
2015 3.256.625.248 21.68%
2016 4.065.932.526 19.9%
2017 9.312.830.201 56.34%
2018 9.626.580.345 3.26%
2019 11.894.748.817 19.07%
2020 15.540.590.965 23.46%
2021 21.849.010.103 28.87%
2022 26.578.845.623 17.8%
2023 30.186.619.945 11.95%
2023 29.914.229.615 -0.91%
2024 31.675.423.329 5.56%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Aier Eye Hospital Group Co., Ltd. Liabilities
Year Liabilities Growth
2006 183.063.943
2007 127.384.367 -43.71%
2008 134.517.419 5.3%
2009 178.081.047 24.46%
2010 304.234.593 41.47%
2011 308.558.295 1.4%
2012 360.929.169 14.51%
2013 380.049.889 5.03%
2014 453.053.556 16.11%
2015 757.420.207 40.18%
2016 1.128.895.551 32.91%
2017 3.840.783.088 70.61%
2018 3.656.030.824 -5.05%
2019 4.872.017.392 24.96%
2020 4.888.415.291 0.34%
2021 9.624.943.005 49.21%
2022 8.963.376.254 -7.38%
2023 10.161.858.405 11.79%
2023 10.098.574.371 -0.63%
2024 11.094.507.216 8.98%

Aier Eye Hospital Group Co., Ltd. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
2.23
Net Income per Share
0.4
Price to Earning Ratio
47.73x
Price To Sales Ratio
8.54x
POCF Ratio
32.12
PFCF Ratio
47.95
Price to Book Ratio
9.08
EV to Sales
8.61
EV Over EBITDA
30.7
EV to Operating CashFlow
32.36
EV to FreeCashFlow
48.32
Earnings Yield
0.02
FreeCashFlow Yield
0.02
Market Cap
176,42 Bil.
Enterprise Value
177,75 Bil.
Graham Number
4.35
Graham NetNet
-0.3

Income Statement Metrics

Net Income per Share
0.4
Income Quality
1.49
ROE
0.19
Return On Assets
0.12
Return On Capital Employed
0.2
Net Income per EBT
0.77
EBT Per Ebit
0.98
Ebit per Revenue
0.24
Effective Tax Rate
0.18

Margins

Sales, General, & Administrative to Revenue
0.03
Research & Developement to Revenue
0.02
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.51
Operating Profit Margin
0.24
Pretax Profit Margin
0.23
Net Profit Margin
0.18

Dividends

Dividend Yield
0.01
Dividend Yield %
0.79
Payout Ratio
0.77
Dividend Per Share
0.15

Operating Metrics

Operating Cashflow per Share
0.59
Free CashFlow per Share
0.4
Capex to Operating CashFlow
0.33
Capex to Revenue
0.09
Capex to Depreciation
2.62
Return on Invested Capital
0.18
Return on Tangible Assets
0.16
Days Sales Outstanding
41.91
Days Payables Outstanding
77.67
Days of Inventory on Hand
35.19
Receivables Turnover
8.71
Payables Turnover
4.7
Inventory Turnover
10.37
Capex per Share
0.2

Balance Sheet

Cash per Share
0,66
Book Value per Share
2,23
Tangible Book Value per Share
1.3
Shareholders Equity per Share
2.1
Interest Debt per Share
0.31
Debt to Equity
0.14
Debt to Assets
0.08
Net Debt to EBITDA
0.23
Current Ratio
1.42
Tangible Asset Value
12,00 Bil.
Net Current Asset Value
-1,50 Bil.
Invested Capital
21335175463
Working Capital
2,83 Bil.
Intangibles to Total Assets
0.27
Average Receivables
2,43 Bil.
Average Payables
2,02 Bil.
Average Inventory
880438746.5
Debt to Market Cap
0.01

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Aier Eye Hospital Group Co., Ltd. Dividends
Year Dividends Growth
2010 0
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2024 0 0%

Aier Eye Hospital Group Co., Ltd. Profile

About Aier Eye Hospital Group Co., Ltd.

Aier Eye Hospital Group Co., Ltd. operates eye care hospitals and institutions. The company offers medical services in the areas of fundus diseases, optometry, refractive correction, glaucoma, corneal diseases, and cataract. It also provides training course for cataract prevention and treatment. The company operates approximately 500 ophthalmic hospitals in mainland China, 86 ophthalmic hospitals in Europe, 1 ophthalmic hospital in the United States, 7 ophthalmic hospitals in Hong Kong, and 12 ophthalmic hospitals in Southeast Asia. The company was founded in 2007 and is headquartered in Changsha, China.

CEO
Mr. Bang Chen
Employee
36.718
Address
New Century Mansion No. 198
Changsha, 410015

Aier Eye Hospital Group Co., Ltd. Executives & BODs

Aier Eye Hospital Group Co., Ltd. Executives & BODs
# Name Age
1 Mr. Li Li
Vice Chairman & GM
70
2 Mr. Zhi Kuan Yang
Deputy General Manager
70
3 Mr. Shibo Tang
Deputy General Manager
70
4 Ms. Li Hua Wang
Deputy General Manager
70
5 Mr. Aiming Li
Deputy General Manager
70
6 Ms. Jun Feng
Deputy General Manager
70
7 Mr. Bang Chen
Founder & Chairman of the Board
70
8 Mr. Duoyuan Liu
Deputy GM & Chief Financial Officer
70
9 Mr. Shi Jun Wu
Deputy GM, Secretary of the Board of Directors & Director
70
10 Mr. Zhong Han
Deputy GM & Director
70

Aier Eye Hospital Group Co., Ltd. Competitors